お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
925319

治療用血漿交換システムの世界市場:成長、動向、予測(2020年~2025年)

Therapeutic Plasma Exchange Systems Market - Growth, Trends, and Forecast (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 120 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.93円
治療用血漿交換システムの世界市場:成長、動向、予測(2020年~2025年)
出版日: 2020年02月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 120 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の治療用血漿交換システム市場は、2020年から2025年にかけて約7.5%のCAGRで成長すると予測されています。市場の成長に起因する主な要因は、自己免疫疾患、血液疾患、循環器疾患の患者数の増加、および老年人口の増加です。たとえば、2020年に発表された「National Institutes of Health report」によると、重症筋無力症の有病率はここ数十年で増加しており、それにより世界中で毎年10万人に約20人が効果的な治療を必要としているため、予測期間中の市場の成長を牽引すると予想されます。

当レポートは世界の治療用血漿交換システム市場について調査しており、市場機会や動向、成長および抑制要因、セグメント別や地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場成長要因
    • 自己免疫および心臓病の世界の有病率の上昇
    • さまざまな適応症への適用に向けての開発や臨床試験の増加
  • 市場抑制要因
    • 高額な治療とデバイス
    • 新興市場における熟練した医療従事者の不足
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 競争の激化

第5章 市場区分

  • 製品別
    • アフェレーシスマシン
    • フィルター
    • その他
  • 症状別」
    • 神経学的障害
    • 心血管疾患
    • 血液疾患
    • 腎障害
    • その他
  • エンドユーザー別
    • 病院
    • 外来手術センター
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ地域
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Asahi Kasei Corporation
    • Baxter International Inc
    • B. Braun Melsungen AG
    • Cerus Corporation
    • Fresenius Kabi AG
    • Haemonetics Corporation
    • Hemacare Corporation
    • IncMedica SpA
    • Kawasumi Laboratories
    • Terumo Corporation

第7章 市場機会および将来動向

目次
Product Code: 67856

The Therapeutic plasma exchange systems market studied was anticipated to grow with a CAGR of nearly 7.5% during the forecast period. The major factor attributing to the growth of the market is an increased number of patients diagnosed with autoimmune diseases, hematology disorders, cardiovascular diseases, and a rise in the geriatric population. For instance, according to the National Institutes of Health report published in the year 2020, the prevalence of myasthenia gravis is increasing in recent decades and affects about 20 per 100,000 people worldwide every year demanding the efficient treatments for the ailments which are likely to fuel the market over the forecast period.

Key Market Trends

The Neurological Disorders by Indication Segment is Expected to Hold the Largest Market Share in the Therapeutic Plasma Exchange Systems Market

  • The Neurological disorders segment is expected to account for the largest revenue over the forecast period. This dominance is owing to the increased demand owing to their proven efficiency in managing neurological conditions such as Guillain-Barre syndrome (GBS), multiple sclerosis and myasthenia gravis. On the other hand, the cardiovascular disorders segment is anticipated to witness the highest growth rate during the forecast period due to increased adoption of TPE as the first line of treatment for various disorders such as arteriosclerosis, rheumatic endocarditis, etc. Furthermore, the technological developments in the segment which increased the applications of TPE in the removal of lipoproteins, fibrinogen, and inflammatory factors, etc, are likely to drive the segment over the forecast period
  • Based on the End-User, the major share of the market is covered by hospitals due to the presence of a huge number of hospitalized patients with cardiac, neurological and renal conditions. Also, the rapid increase in favorable reimbursement policies and rise in the number of physicians shifting from private clinics to large scale hospitals are expected to propel the hospital segment during the forecast period

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall therapeutic plasma exchange systems market throughout the forecast period. The dominance is due to a rise in the global prevalence of various autoimmune disorders, a steep rise in the adoption of the lipoprotein apheresis treatment for cardiovascular indications like CAD, hypercholesterolemia strokes and atherosclerosis with an increased rate of cardiac deaths in recent years. For instance, according to The American Heart Association, in 2018, nearly 92.1 million individuals in the U.S. suffered from cardiovascular diseases resulted in higher demand for TPE driving the market in the region. Also, increased availability of advanced technology and established healthcare infrastructures in the region is also likely to fuel the market over the forecast period.

Competitive Landscape

The therapeutic plasma exchange systems market is moderately competitive and consists of several major players. Some of the companies are expanding their market position by adopting various strategies such as acquisitions and mergers, while others are developing new methods for the treatment and introducing new products to maintain their market share. For Instance, In April 2017, Terumo BCT received the first and only CE mark approval for its Spectra Optia Apheresis System to treat Guillain-Barre syndrome (GBS) and myasthenia gravis (MG) using Therapeutic Plasma Exchange in the European Market fueling the market revenue share. Few of the major players currently dominating the industry in terms of revenue are Asahi Kasei Corporation, Baxter International Inc, Terumo Corporation, B. Braun Melsungen AG, and Fresenius Kabi AG

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Global Prevalence of Autoimmune and Cardiac Diseases
    • 4.2.2 Growing R&D Activities and Clinical Trials to Increase the Application in Various Indications
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment and Devices
    • 4.3.2 Lack of Skilled Healthcare Professionals in Emerging Markets
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Products
    • 5.1.1 Apheresis Machine
    • 5.1.2 Filters
    • 5.1.3 Others
  • 5.2 Indication
    • 5.2.1 Neurological Disorders
    • 5.2.2 Cardiovascular Disorders
    • 5.2.3 Hematology Disorders
    • 5.2.4 Renal Disorders
    • 5.2.5 Others
  • 5.3 End-User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United states
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Asahi Kasei Corporation
    • 6.1.2 Baxter International Inc
    • 6.1.3 B. Braun Melsungen AG
    • 6.1.4 Cerus Corporation
    • 6.1.5 Fresenius Kabi AG
    • 6.1.6 Haemonetics Corporation
    • 6.1.7 Hemacare Corporation
    • 6.1.8 IncMedica S.p.A.
    • 6.1.9 Kawasumi Laboratories
    • 6.1.10 Terumo Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.